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A B S T R A C T
Objective: Adverse drug events (ADEs) can cause serious harm to patients and can lead to
hospitalization or even death. ADEs are a burden not only to patients and their relatives, but
also to society and have the potential to involve high costs. To provide more information on
the economic burden of preventable adverse drug events of outpatients, we performed a
cost study on the data collected in the Hospital Admissions Related to Medication (HARM)
study. In this study we examined the frequency, preventability, and risk factors for hospital
admissions related to medication.
Methods: The average costs for a preventable medication-related hospital admission were
calculated by summing the direct medical costs and the production losses of all the pre-
ventable admissions, taking into account the different types of hospitals (academic and
general) and the age of the admitted patients.
Results: The average medical costs for one preventable medication-related hospital admis-
sion were €5461. The average production loss costs for one admission were €1712 for a
person younger than 65 years of age. Combining the medical costs and the costs of produc-
tion losses resulted in average costs of €6009 for one, potentially preventable, medication-
related hospital admission for all ages.
Conclusions: The costs of potentially preventable hospital admissions related to medica-
tion are considerable. Therefore, patient safety interventions to prevent ADEs and hospital
admissions may be cost-effective or even cost saving.
Copyright © 2011, International Society for Pharmacoeconomics and Outcomes Research
(ISPOR). Published by Elsevier Inc.
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dverse drug events (ADEs) can cause serious harm to pa-
ients and can lead to hospitalization or even death [1,2]. Ad-
erse drug events are not only a burden to patients and their
elatives but also to society, potentially involving high costs
3–5]. On one hand, improvement of medication safety and
atient safety is a major concern to health care workers and
olicymakers and has the potential to reduce health care
osts; however, increasing budgetary constraints often ham-
er investments in patient safety improvements. Thus, more
nsight into the costs of preventable hospital admissions may
elp to prioritize areas to improve patient safety from an eco-
omic perspective in addition to the patient and health care
erspective.
Some information is already available on costs associated
ith adverse events and preventable adverse events that oc-
ur inside hospitals. A study in the United States estimated
he costs attributable to an ADE at $2595 for all ADEs and $4685
or preventable ADEs in 1997. Based on these costs and data
bout the incidence of ADEs, the authors extrapolated that the
nnual costs attributable to all ADEs and to preventable ADEs
or a 700-bed teaching hospital would be $5.6 million and $2.8
illion, respectively [3].The direct medical costs in Dutch hos-
itals [4] (total number of beds in The Netherlands: 54,353 [6])
ere estimated at a total of €355 million for all adverse events
not just events caused by drugs) and €161 million for prevent-
ble adverse events in 2004, which is 1.1% of the expenses of
he Dutch health care budget [7].
Information on costs of outpatient adverse drug events
eading to hospital admissions is still lacking in The Nether-
ands, but some information is available from studies per-
ormed in the United States and the United Kingdom. Esti-
ates of the costs of one medication-related hospital
dmission vary from US$1507 to US$8300 [8,9]. Exchanging
K£ into US$, a large study in the United Kingdom estimated
hese costs at the lower range of this interval. Patel et al. [1]
lso suggested that these admissions cost the NHS up to £466
US$786; €542) million annually, which is 0.59% of the British
ealth care budget [10]. Unfortunately, only direct medical
osts were reported [11], and many of the published studies
ere either limited to only one [12] or two hospitals, individual
nits, or patient groups [8,13], or reported no information on
reventable costs [14,15].
Given the wide range of costs mentioned in literature and
he need for information on the economic burden of prevent-
ble adverse drug events of outpatients, we performed a cost
nalysis on the data we had previously collected in the Hos-
ital Admissions Related to Medications (HARM) study [2]. The
revious HARM study was a prospective, multicenter, case-
ontrol study in which we collected data on approximately
3,000 unplanned admissions in 21 hospitals in The Nether-
ands. Results revealed that 5.6% (n  714) of hospital admis-
ions were thought to be medication related. One-half of these
n 332) were considered to be potentially preventable. In the
urrent study, we present the total short-term costs associ-
ted with preventable medication-related hospital admis- bions. In addition, we report costs of different subgroups of
dmissions based on type of hospital, age, preventability, and
eason of admission to gain further insight into the potential
izes and areas for cost savings attributable to possible strat-
gies to prevent ADEs.
ethod
etting and study population
ata were collected from the prospective, multicenter, case-
ontrol, HARM study on medication-related hospital admis-
ions, which has been described in more detail in a previous
ublication [2]. Briefly, in this study 12,793 unplanned (acute)
dmissions from 4 university and 17 general hospitals from all
egions in The Netherlands were screened for a potential
edication-related cause of hospitalization. An unplanned
dmission was defined as an admission that was not sched-
led by the hospital 24 hours before the actual admission. A
ase-control design was used to determine risk factors for po-
entially preventable admissions. Controls were patients ad-
itted for elective surgery. The exclusion criteria were age
ounger than 18 years and admission for obstetric indications,
o a psychiatric ward, or for self-poisoning. The causality as-
essment of admissions was done by using a three-step ap-
roach (trigger list, confirmation by a physician, and central
ssessment). The central causality assessment was per-
ormed by two independent clinical pharmacists according to
n adjusted version of the algorithm by Kramer et al. [2,16]. In
he adjusted version of the algorithm by Kramer et al., three
uestions are to be answered (in contrast to six questions in
he original algorithm): whether the reason for admission is
nown to be an adverse event of the suspected medicine,
hether alternative causes can explain the relationship be-
ween the suspected medicine and the adverse event, and
hether a plausible time relationship exists between the ad-
erse event and the start of medication administration (or the
ccurrence of the medication error). On the basis of the an-
wers, causality is classified as possible, probable, or unlikely.
ases with an assessment of unlikely were excluded. Prevent-
bility also was assessed centrally according to a modified
ersion of the algorithm by Schumock et al. [2,17]. In this al-
orithm, an admission was assessed as potentially prevent-
ble when a medication error was made with the medication
hat caused the hospital admission. If the assessments of the
harmacists were not in agreement, they met and discussed
o reach a consensus. This resulted in 714 (5.6%) medication-
elated hospital admissions, of which 332 (46%) were consid-
red potentially preventable. The median length of hospital
tay of the 332 potentially preventable medication-related
ases was 8 days, and 24 (7.2%) of these patients were admit-
ed to an intensive care unit (ICU). Lack of a clear indication for
he medication, nonadherence to the medication regimen, in-
dequate monitoring, and drug–drug interactions were the
ost common medication errors found. Most of the included
dmitted patients had much comorbidity: 56% had four or
ore diseases in their medical history. In addition to the num-er of comorbidities, other risk factors to medication-related
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36 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 3 4 - 4 0ospital admissions were identified: impaired cognition, im-
aired renal function, dependent living situation, nonadher-
nce to the medication regimen, and polypharmacy [2].
For inclusion in the cost analysis, the HARM admissions
ad to comply with the following inclusion criteria: poten-
ially preventable and availability of information on type of
dmitting hospital (university or general hospital), length of
tay in hospital, length of stay in an ICU during the admission,
eason for admission, and age of the patient.
ata collection
f the 332 potentially preventable medication-related hospi-
al admissions, one admission was excluded because of lack of
nformation on length of stay. For all 331 remaining poten-
ially preventable admissions, data were collected on visits to
he emergency department, length of hospital stay, and
ength of stay in an ICU. Other admissions, such as controls
nd nonmedication-related and nonpreventable admissions,
ere not included in this costing study. Based on the three
tems mentioned, a cost estimate was performed using sepa-
ate prices for university and general hospitals [18]. For a sub-
et of 153 of the included HARM admissions (one university
ospital and three general hospitals), it was possible to re-
rieve more detailed information on diagnostic tests, treat-
ent during hospitalization (including medication), specialist
onsultations, and transportation by ambulance by medical
hart review. This information was used to determine a more
recise cost estimate for this subset.
edical costs
or the subset of 153 HARM admissions, all costs to the health
are system were identified during the hospital admission,
oth related and unrelated to the adverse drug event. For ev-
ry included admission, all costs were valued according to the
utch Manual for Costing in economic evaluations [18,19]. Ap-
lication of this manual is recommended according to the
utch guidelines for pharmacoeconomic research [20]. All of
he identified costs were summed for every admission and
eflated up to the year 2006, the year in which the data were
ollected.
roduction loss
ost productivity of patients during admission in hospital also
as valued for the 331 included admissions. Productivity costs
ncluded cost estimates for time off work and reduced produc-
ivity on the job. Based on the friction-costing method, stan-
ardized costs per day were derived from the costing manual
ccording to the sex and age of the admitted patient, up to the
ge of 65 [21]. The costs for all 331 admissions then were cal-
ulated by multiplying the number of days admitted to hospi-
al by the costs per day. As this figure will overestimate the
roductivity costs because colleagues often undertake the ab-
entees’ work during normal working hours and after short-
erm absence productivity is compensated also by the patient
uring normal working hours, absence from work may notead to a productivity loss corresponding to 100% of the ab- aence [22]. This compensating mechanism is taken into ac-
ount within the friction-costing method by applying an elas-
icity factor. This elasticity factor reflects the change in
roduction compared with the change in labor time. Costs of
bsence from work shorter than the friction period were cal-
ulated as being 80% of the production value during the period
f absence (assuming a heterogeneous labor market and labor
ime elasticity of production  0.8 [23]). The friction period
as not explicitly taken into account because production
osses were counted only during hospitalizations, which were
ll within the assumed friction period (123 days) [18,23]. Note
hat this is a conservative method of estimating productivity
oss. It is limited to the production loss during the admission
nly, whereas it might be expected that days of absence from
ork extend beyond the actual days of admission.
xtrapolation
medical costs multiplier was calculated to estimate all of the
irect medical costs of all preventable medication-related
ospital admissions. This multiplier was based on the detailed
ata from the subset of 153 HARM admissions from four hos-
itals, separately for the different type of hospitals, and was
ubsequently applied to the other hospitals lacking this de-
ailed information. For the subset of 153 HARM admissions,
rstly the standardized costs (A) [18,19] of the emergency
oom (ER) visits, time spent on an ICU, and standard costs of
he total number of bed days were summed. Secondly, all
edical costs related to, for example, diagnostic tests, treat-
ent during hospitalization (including medication), specialist
onsultation, and transportation by ambulance were retrieved
y medical chart review and using hospital billings (B). The
um of the standardized and other medical costs were then
alculated (A B) and divided by the standardized costs (A) to
erive the multiplier used to inflate the costs for ER, ICU, and
ther bed days to totals for those hospitals lacking the detailed
nformation.
Ergo, the total medical costs of the preventable admissions
ere calculated by summing the standard costs of a day in the
pecific type of hospital times the number of bed days, the
osts of time spent on an ICU, and visits to the accident and
mergency rooms, and subsequently multiplying this by the
ultiplier according to the type of hospital.
The average costs for a preventable medication-related
ospital admission were calculated by summing the direct
edical costs of all the preventable admissions together with
he production losses of all the preventable admissions, tak-
ng into account the different types of hospitals and different
ge groups, divided by the total number of included prevent-
ble admissions. These average costs per preventable admis-
ion were extrapolated to the Dutch situation using national
dmissions data regarding the type of hospital and the differ-
nt age groups.
ubgroups
he abovementioned cost calculations were performed also
or different groups of admissions and for specific reasons for
dmission within the sample of 331 admissions, which often
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37V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 3 4 - 4 0ere related to medication. The most common reasons for
edication-related hospitalization were gastrointestinal tract
roblems (15%) such as gastrointestinal bleeding, constipa-
ion, and diarrhea. Other common problems were cardiovas-
ular symptoms (11%), respiratory symptoms (8%), and poor
lycemic control (6%). Furthermore, the costs were evaluated
or admissions of people younger than 65 and older than 65
ears of age, separately.
esults
edical costs
he 331 potentially preventable medication-related hospital
dmissions included in this study accounted for 3571 normal-
are inpatient days, with a total cost of €1,486,999, which ap-
eared to be the main cost driver. Twenty-four of the 331 pa-
ients also were admitted to an ICU, accounting for an extra 82
ays at an ICU corresponding to a cost of €143,684. The cost of
R visits for the preventable admissions was €47,874. Costs
ere calculated for every HARM admission including normal-
are inpatient days, ICU stay, and ER visits and summed, re-
ulting in €1,678,556 or US$2,438,606 in total (€1.00 is US$1.45;
xchange rate January 2010). The average cost for one prevent-
ble admission was €5071 or US$7367, before applying the
ultipliers.
In the subset of 153 cases, more detailed costs were retrieved.
his resulted in additional costs amounting to approximately
0% of the total admission costs. These costs consisted of trans-
ortation by ambulance to the hospital at the time of admission
€14,179), specialist consultation during admission (€8409),
pecialist consultation at admission (€12,254), and medical
rocedures (including diagnostic tests) (€148,988). The de-
ailed cost estimate of the subset was used to estimate the
ultiplier at 1.22 for the admissions to a general hospital and
.18 for the admission to a university hospital. Applying these
ultipliers to the cost estimates of every admission resulted
n total medical costs for 331 admissions of €1,807,549 or
S$2,626,007. The average of more detailed medical costs for
ne preventable admission was €5461 or US$7934, inclusive of
Table 1 – Cost outcomes in € of potentially preventable hos
hospital and age group.
All hospitals c
Younger than 65 years
Medical costs one admission 50
Productivity loss costs one admission 17
Total costs one admission 68
Total costs per year in The Netherlands 38,755,4
65 years and older
Medical costs one admission 56
Productivity loss costs one admission
Total costs one admission 56
Total costs per year in The Netherlands 55,656,4
Total costs
Per admission 60
Per year in The Netherlands 94,411,9he application of the multipliers.roduction loss
he total costs of production loss were estimated at €181,528
r US$263,723 for all 331 studied admissions. The average pro-
uction loss costs for one admission were €1712 for a person
ounger than 65 years of age. The total production loss costs
or one admission varied between €61 for a 19-year-old man
ho was admitted for 1 day to €13,234 for a 37-year-old man
ho was admitted for 38 days to the hospital (excluding those
ged 65 years and over with theoretical costs of production
osses at €0).
xtrapolation
ombining the medical costs and the costs of production
osses resulted in an average of €6009 for one potentially pre-
entable, medication-related hospital admission. We extrap-
lated this figure to the Dutch health care system which re-
ulted in the total costs of over €94 million or US$137 million in
ne year. With the extrapolation, we took the different types
f hospitals into account.
Of this total, €86 million is estimated to be attributable to
edical costs. These direct medical costs reflect 0.49% of the
otal hospital care budget in The Netherlands (Table 1).
ubgroups
osts of a medication-related hospital admission in a university
ospital were estimated to be higher (€8453) than in a general
ospital (€5748) because of higher inpatient day costs in univer-
ity hospitals. Yet, the total costs of medication-related hospital
dmissions in one year were lower in university centers (almost
14 million) than the admission costs in general hospitals (al-
ost €81 million) because the total amount of admissions to
niversity hospitals is less than to general hospitals.
The average total costs of one admission for patients 65 years
nd older (€5637) were estimated to be lower than for younger
atients (€6800). Taking into account the medical costs only, the
dmission costs of an elderly patient were higher (€5637) than
he costs of a younger patient (€5088), reflecting the different
mpacts of production losses in both age groups.
l admissions related to medication, divided by type of
ined University hospital General hospital
7678 4558
1604 1734
9283 6292
7,481,761 31,273,706
7386 5521
0 0
7386 5521
6,330,076 49,326,382
8453 5748
13,811,837 80,600,088pita
omb
88
12
00
67
37
0
37
58
09The costs of the most common potentially preventable rea-
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38 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 3 4 - 4 0ons for admission to hospital related to medication are pre-
ented in Table 2. The total costs of admissions for problems
f the gastrointestinal system were estimated to be the high-
st (over €17 million), followed by cardiovascular problems
nd respiratory tract problems (both over €8 million) and ad-
issions related to the endocrine system (€5 million).
omment
xtrapolation of the results of this study shows that the total
osts associated with preventable medication-related hospi-
al admissions in The Netherlands are more than €94 million.
ighty-six million euro of the €94 million is attributable to
edical costs. This reflects 0.21% of the total health care costs
nd 0.49% of the hospital costs in The Netherlands. The main
ost driver is bed occupancy, and therefore, costs are highly
ependent on length of stay in hospital, which in our frame-
ork also largely determined other cost components, such as
roduction loss.
The median length of hospital stay in our patient group at
days [2] is similar to the United Kingdom study by Pirmo-
amed et al. [1], but the average costs per inhabitant are lower
n our study: €5.9 per person in The Netherlands per year ver-
us €9 per person in the United Kingdom per year. This differ-
nce can be explained by the selection of admissions. We cal-
ulated only the costs of potentially preventable admissions,
hereas all medication-related admissions were taken into
ccount in the United Kingdom study. The total costs of one
ospitalization of €8453 in a university hospital and €5748 in a
eneral hospital are within the range of previously published
maller studies [8]. The estimated total annual cost of more
han €94 million reflects a considerable amount and justifies
nvestments in patient safety that might not only prevent
uch adverse events, but also might even be cost saving.
Our study has a number of limitations. Firstly, our cost
stimation may be too conservative. The frequency of medi-
ation-related hospitalizations may be underestimated be-
ause of the conservative assessment of admissions using a
hree-step approach. On the other hand, this approach is
ikely to result in high specificity, adding to the reliability of
he results. Secondly, we accounted only for short-term costs:
edical costs during the hospital admission and production
Table 2 – Cost outcomes of potentially preventable hospita
reason for admission.
Reason for admission Number of
admissions
n (%)
Dire
c
adm
Gastrointestinal system
Gastrointestinal tract bleeding 48 (14.5)
Other gastrointestinal tract symptoms
(e.g., diarrhea, constipation)
22 (6.6)
Circulatory system: cardiovascular symptoms
(e.g., dysrhythmias, heart failure)
35 (10.5)
Respiratory symptoms (e.g., dyspnea) 26 (7.8)
Endocrine system: hypoglycemia or
hyperglycemia
20 (6.0)oss costs incurred from the time in hospital only. Neither vosts related to referral to a tertiary care center or outpatient
ealth care after discharge nor nonmedical direct costs such
s travel costs to and from the hospital were taken into ac-
ount. Productivity loss after discharge was not taken into
ccount. It might be expected that days of absence from work
xtend beyond the actual period of the admission only. All this
ay have led to an underestimation of the costs. Furthermore,
lthough a thorough search was performed of the medical
harts of the included patients, noninvasive procedures are
ften underreported, whereas surgical interventions are well
ocumented. Because noninvasive procedures are not cost-
rivers, we do not expect that this has led to major distortions
n our results. We note also that production loss costs may
ave been slightly overestimated. The included patients in the
ARM study had a relatively high incidence of comorbidities,
nd therefore, are more likely to be chronically ill and more
ikely to be less productive. On the other hand, the production
oss accounts for only 8% of the total costs; therefore, the over-
stimation of the total costs is only a few percent.
The design of the initial HARM study was such that admis-
ions to a psychiatric ward were excluded as well as admissions
f children and pregnancy-related admissions. The frequency of
edication-related admissions to a psychiatric hospital or hos-
ital ward can be especially considerable (10% [24] to 23% [25]);
herefore, exclusion of these admissions may result in an under-
stimation of true costs. With this costing study based on the
ARM study, the calculated costs are limited to medication-re-
ated problems that arose before admission to hospital. The cal-
ulated costs do not include the costs from adverse drug events
hat occurred during the admission and might have prolonged
tay in hospital or transfer to the ICU. Our study was done for The
etherlands. Obviously, our cost estimates may not be extrapo-
ated in a straightforward fashion to other countries with differ-
nt health care systems, different relative costs between re-
ource-use components, and different use of medications.
Despite the limitations in our study, the data used in this
osting study may be considered reliable because they are ob-
ained from a large representative sample of Dutch hospitals,
ith screening of a large number of admissions from many
atient groups and wards, thus providing reliable information
n the burden of the problem and on potentially preventable
osts. Furthermore, the thorough method of medical chart re-
issions related to medication, divided by most common
edical
per
ion (€)
Production loss
costs per
admission (€)
Total costs per
admission (€)
Total costs per
year in The
Netherlands (€)
7 33 5060 11,390,826
1 877 5689 5,870,687
3 774 5096 8,363,286
0 761 6751 8,229,041
6 367 5663 5,311,521l adm
ct m
osts
iss
502
481
432
599
529iew of a large unbiased sample of admissions resulted in a
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39V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 3 4 - 4 0onsistent and robust multiplier to determine the actual costs
f the hospital admissions.
Based on the findings from the HARM study, combined
ith this costing study, several recommendations can be
ade. First, we recommend review of the medication of high-
isk patients (e.g., elderly patients with polypharmacy) for po-
ential medication-related problems. The focus in a review
hould be on the medication errors identified in the HARM
tudy to prevent these admissions and save costs. Therefore,
educing overprescription, improving compliance, monitoring
rug therapy, and preventing drug–drug interactions may
ave costs if these actions result in lowering the frequency of
edication-related hospitalizations [26].
Second, when analyzing the most common reason for ad-
ission combined with the costs, some interventions might
e considered to prevent these costs. The provision of gastro-
rotection for nonsteroidal anti-inflammatory drug (NSAID)
sers is effective to prevent gastrointestinal events [27,28] and
s also cost effective although this is mostly dependent on the
rice of the protective treatment, which can differ in different
ealth care settings [29,30]. Monitoring of blood glucose levels
n diabetic patients can prevent hypoglycemia or hyperglyce-
ia [31] and will be cost effective in certain patient groups
32,33]. Several laxatives are effective to treat constipation
34,35], but there are not sufficient data on cost-effectiveness
f different laxatives and treatment strategies in the manage-
ent of constipation or opiate-related constipation. Medica-
ion-related constipation was detected as an important prob-
em in the HARM study. Further study is required into the
ost-effectiveness of these recommendations in reducing the
isks of medication-related hospitalizations for certain pa-
ient groups. In addition, more information is required on di-
ect medical costs and indirect costs, related to the medica-
ion-related admissions, after discharge from hospital.
onclusions
he cost estimates of potentially preventable hospital admis-
ions related to medication are considerable. Insight into the
ubclasses of medication-related hospitalizations that are re-
ated with the highest costs offers a starting point for patient
afety interventions, which may be cost-effective or even cost
aving.
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